MedKoo Cat#: 531383 | Name: PF-04279405
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PF-04279405 is a potent and selective glucokinase activator.

Chemical Structure

PF-04279405
CAS#955881-01-3

Theoretical Analysis

MedKoo Cat#: 531383

Name: PF-04279405

CAS#: 955881-01-3

Chemical Formula: C25H25FN4O4

Exact Mass: 464.1860

Molecular Weight: 464.50

Elemental Analysis: C, 64.65; H, 5.43; F, 4.09; N, 12.06; O, 13.78

Price and Availability

Size Price Availability Quantity
5mg USD 500.00
25mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PF-04279405
IUPAC/Chemical Name
4-[4-(1-Azetidinylcarbonyl)-3-fluorophenoxy]-2,3-dihydro-2,2-dimethyl-N-(1-methyl-1H-pyrazol-3-yl)-6-benzofurancarboxamide
InChi Key
MDMLUBFZTGYEGP-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H25FN4O4/c1-25(2)14-18-20(33-16-5-6-17(19(26)13-16)24(32)30-8-4-9-30)11-15(12-21(18)34-25)23(31)27-22-7-10-29(3)28-22/h5-7,10-13H,4,8-9,14H2,1-3H3,(H,27,28,31)
SMILES Code
O=C(C1=CC(OC2=CC=C(C(N3CCC3)=O)C(F)=C2)=C4CC(C)(C)OC4=C1)NC5=NN(C)C=C5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
PF-04279405 is a potent and selective glucokinase activator.
In vitro activity:
TBD
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 464.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
Pettersen JC, Litchfield J, Neef N, Schmidt SP, Shirai N, Walters KM, Enerson BE, Chatman LA, Pfefferkorn JA. The relationship of glucokinase activator-induced hypoglycemia with arteriopathy, neuronal necrosis, and peripheral neuropathy in nonclinical studies. Toxicol Pathol. 2014 Jun;42(4):696-708. doi: 10.1177/0192623314526006. Epub 2014 Apr 24. PMID: 24771080. Zager MG, Kozminski K, Pascual B, Ogilvie KM, Sun S. Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes. J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):127-39. doi: 10.1007/s10928-014-9351-7. Epub 2014 Feb 28. PMID: 24578187.